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Abstract
Background: X-linked hypophosphatemic rickets (XLH) is the first cause of inherited hypophosphatemia and is
caused by mutation in the PHEX gene, resulting in excessive expression of the phosphaturic factor FGF23.
Symptoms are mainly related to rickets in children and osteomalacia in adults and cause several complications that
can be highly invalidating. Due to its rarity, XLH is poorly known and diagnosis is frequently delayed. Conventional
treatment is based on oral phosphate salts supplementation and activated vitamin D analogs, which however, cannot
cure the disease in most cases.
Objective: Due to the low prevalence of XLH, an experts’ opinion survey was conducted across Italian centers to
collect data on XLH and on its management.
Methods: A questionnaire was developed by a group of experts to collect data on XLH epidemiology, diagnosis and
treatment in Italy.
Results: Data from 10 Italian centers (nine of which pediatric) on 175 patients, followed between 1998 and 2017, were
included in the survey. Most patients were followed since childhood and 63 children became adults during
the investigated period. The diagnosis was made before the age of 1 and between 1 and 5 years in 11 and
50% of cases, respectively. Clinically apparent bone deformities were present in 95% of patients. These were
ranked moderate/severe in 75% of subjects and caused growth stunting in 67% of patients. Other frequent
complications included bone pain (40%), dental abscesses (33%), and dental malpositions (53%). Treatment
protocols varied substantially among centers. Nephrocalcinosis was observed in 34% of patients. Tertiary
hyperparathyroidism developed in 6% of patients.
Conclusions: XLH remains a severe condition with significant morbidities.
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Background
X-linked hypophosphatemic rickets (XLH) (OMIM
307800) is a rare disease caused by mutations in the
PHEX gene. The gene encodes for an endopeptidase that
is primarily expressed on the surface of osteoblast, oste-
ocytes, odontoblasts and cementoblasts [1, 2]. The dis-
ease follows an X-linked mode of transmission with
dominant expression, and represents the first cause of
hypophosphatemic rickets [1]. Female carriers usually
present symptoms similar to male patients [3]. Unless
patients are identified by family screening, they are usu-
ally diagnosed in the first years of life after noticing bow-
ing of the lower legs, delayed walking, abnormal walking
gait, and/or growth stunting. The disease may be initially
misdiagnosed for vitamin D deficiency, but biochemical
investigations and in some cases, lack of response to
vitamin D supplements usually allow the diagnosis. Typ-
ically, patients show at diagnosis low serum phosphate
levels secondary to increased phosphaturia, elevated al-
kaline phosphatase, normal parathyroid hormone (PTH)
levels and low-normal urine calcium. X-rays demon-
strate typical features of rickets without significant bone
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resorption, as opposed to rickets secondary to vitamin D
deficiency [1, 4]. Growth plates of long bones have a
cupped appearance, with increased thickness and irregu-
larities. Positive family history often facilitates the diag-
nosis, but de novo mutations occur frequently and some
adults lack overt features of XLH [5].
Other frequent symptoms in children include rachitic
rosary, dolichocephaly with parietal flattening and frontal
bossing, and bone pain. More rarely, patients are diag-
nosed with craniosynostosis, type 1 Chiari malformations,
intracranial hypertension or hearing impairment [5, 6].
The majority of children with overt XLH grow asymmet-
rically. They have slightly decreased sitting height and
markedly decreased leg length. Patients often have dental
symptoms secondary to dental malpositions and/or to
hypomineralization of dentine and hypoplasia of the en-
amel, which cause frequent abscesses [1, 5, 6].
Adult patients usually present with symptoms second-
ary to defective bone mineralization (osteomalacia) and
often complain of bone and joint pain [7]. They fre-
quently develop pseudofractures, as well as invalidating
osteoarthropathies that involve predominantly the an-
kles, knees and sacroiliac joints [7]. They can also de-
velop enthesopathy, which is caused by calcification of
tendons and ligaments. These are particularly prominent
in the ankles, knees, pelvic joints and spine [8, 9].
The above symptoms highlight the severity of the dis-
ease, which may not be recognized due to its rarity. For
this same reason clinical and biochemical data on large
cohorts of patients are scanty.
On these premises, we have conducted a survey in ten
Italian reference centers for the diagnosis and treatment
of XLH, to evaluate the epidemiology of the disease,
diagnostic challenges, treatment attitudes, organization
of care and disease burden.
Methods
A questionnaire was developed by a group of experts to
collect retrospective data on XLH in Italy. The experts
met initially in September 2016 and subsequently twice
to elaborate the questionnaire, analyze the initial results
and solve open issues to finalize data collection. The sur-
vey was limited to data that could be collected reliably
from medical charts. Single patient data were not trans-
ferred; only aggregate data from each center were col-
lected, to protect privacy. Patients were included in the
study if the following data were retrievable from clinical
charts: diagnosis, epidemiology and treatment pattern.
Patients were excluded if such data were not available.
The diagnosis of XLH was based on genetic confirm-
ation of a PHEX mutation, or, if not available, was based
on symptoms, family history, radiological evidence of
rickets, and laboratory tests.
Ten units were identified in North and Central Italy
after screening pediatric, endocrinology and nephrology
units for their expertise in XLH, as well as regional
registries for rare diseases.1 The centers included in the
study were selected based on: (i) number of patients
treated every year and inclusion in the National Network
for rare diseases. The questionnaire investigated the fol-
lowing disease areas: epidemiology, diagnosis, disease se-
verity, treatment, organization of care.
Quality of life data were not available in the charts,
therefore, the impact of the disease burden was esti-
mated by the clinicians, using a 5-point scale (1: low
impact, 5: high impact), inspired from the EUROQOL
questionnaire, exploring various dimensions of daily
life (functional capacity, mobility, usual activities,
pain/discomfort).
Descriptive statistical analyses were used to illustrate
data. Results are expressed as mean ± standard deviation
(SD), median and range or percentage, as appropriate.
Results
Data from 175 patients that were followed between 1998
and 2017 in the 10 participating centers were included
in the survey (Table 1).
Most centers were pediatric units, therefore data on
adult patients were limited. Twenty-two patients were
diagnosed before 1998 and followed afterwards. Of the
153 patients (75% males and 25% females) diagnosed
after 1998, 135 were pediatric (0–17 years of age). For
most criteria, data were available for all patients; how-
ever, some data could not be traced back from all med-
ical charts or were restricted to pediatric patients.
Diagnosis
The distribution of the age at diagnosis is reported in
Table 2. Such info was available for 150 patients only; of
those, over 60% were diagnosed between 1 and 5 years
No trends towards earlier diagnosis in recent years was
observed by comparing patients diagnosed after and be-
fore 2012 (data not shown).
A genetic test was performed in 65 patients and a
pathogenic PHEX mutation was confirmed in 56 cases
(86%). For the reminder of the cohort, the diagnosis was
based on clinical grounds. Physicians from the 10 cen-
ters were hence asked to rank the most important fea-
tures leading to the diagnosis of XLH. These included
rickets, hypophosphatemia and, when available, a posi-
tive family history. Interestingly, 17% of patients had
been diagnosed with vitamin D deficiency prior to the
diagnosis of XLH. Overall, positive family history was
present in 33% (54/164) of patients in which the infor-
mation was available.
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Symptoms
Most (94,8%) patients had lower leg deformities, which
were ranked severe in 28%, moderate in 47%, and mild
or absent in the remainder 25% of patients. “Severe” de-
formities referred to overt genu valgus or genu varum
that impaired normal walking, “moderate” to less im-
portant deformities with mild or no walking impairment,
and “mild” to minor limb deformities with regular joint
alignment (Fig. 1).
Bone pain was reported in two third (65,6%) of pa-
tients but was ranked as mild to moderate in most
(79,3%) cases. More than half (67%) of patients had
growth retardation (height lower than − 2 SD). Scoliosis
or osteopenia was seldom reported. Pathological frac-
tures were observed in nearly one third of patients. Cra-
niosynostosis was reported in 5% of the cohort. Dental
malpositions were present in half of patients (53%) and
approximately one third (33%) had experienced at least
one dental abscess. Hearing impairment and neuro-
logical problems were infrequent (observed in 5 and 9%
of cases, respectively - Table 3).
Medical and orthopedic treatment
All centers prescribed conventional treatment to all
pediatric patients, including oral phosphate supplements
and active vitamin D analogues, namely calcitriol and
alfacalcidol. The latter was generally preferred in young
children because liquid solutions are commercially avail-
able in Italy. In some centers non-active vitamin D sup-
plements were also prescribed. Doses were modified
according to age, but the dose range was considerably
wide. For example, the dose of calcitriol for school age
children ranged from 0.25 to 2.0 mcg/day. In some
centers, doses of vitamin D was calculated according to
weight, while other centers used fixed doses and adapted
treatment according to the biochemical response. Phos-
phate salt prescription was equally very variable. For
school age children, the dose varied from 15 to 60 mg/
Kg/day. Phosphate was prescribed in different pharma-
cologic preparations, including using IV solution for oral
administration, galenic solutions (Joulie or modified Jou-
lie solutions), and commercially available tablets or li-
quid solutions, some of which were imported from other
European countries. The frequency of uptake also varied,
but most centers prescribed four doses per day in pread-
olescent patients and usually reduced the frequency to
2–3 doses per day in adolescents. Two centers did not
recommend systematic treatment in adults, while the
remaining centers advocated to continue low dose treat-
ment with phosphate supplements and/or vitamin D,
irrespectively to the presence of symptoms.
Likewise, metabolic targets for optimal disease control
were, to some extent, different between centers. Unani-
mously, normalization of alkaline phosphatase was the
main biochemical marker of a satisfactory treatment,
with optimal target values within the normal range and
acceptable values below 1.5-fold the upper limit of nor-
mal range for age. All experts tried to keep serum cal-
cium and PTH levels within the normal range. In six
centers, serum phosphate levels did not represent a tar-
get for treatment. Nonetheless, four centers aimed at
serum phosphate levels above a given threshold, ranging
2–3 mg/dl.
Complications of conventional treatment include
nephrocalcinosis and hyperparathyroidism. Retrospective
evaluation of renal ultrasound did not allow ranking the
severity of nephrocalcinosis. Likewise, hyperparathyroid-
ism was difficult to assess and for consistency, only pa-
tients requiring surgery or treatment with cinacalcet for
tertiary hyperparathyroidism were recorded. Overall,
nephrocalcinosis was reported in 34% of patients, while
tertiary hyperparathyroidism was developed in 6%.
From the orthopedic standpoint, half of patients had
undergone at least one surgical procedure. These in-
cluded osteotomies and epiphysiodesis, with the latter
procedure being more frequently used in recent years.
More detailed analyses were not possible due to the
Table 1 Total number of patients managed and origin
Lombardia (Milan - 3
centres)
Piemonte
(Torino)
Liguria
(Genoa)
Emilia-Romagna
(Bologna)
Toscana (2 centres:
Pisa and Florence)
Lazio (Rome - 2
centres)
TOT
Total number of patients 44 19 3 18 46 45 175
Patients from the same region 33 14 0 4 20 30 101
% 75% 74% 0% 22% 43% 67% 58%
Patients from other regions 11 5 3 14 26 15 74
% 25% 26% 100% 78% 57% 33% 42%
Table 2 Age at diagnosis in patients diagnosed after 1998
Age at diagnosis Number of patients
(1998–2017)
%
0–1 years 17 11%
1–5 years 75 50%
5–12 years 35 23%
12–17 years 6 4%
≥18 years 17 11%
TOTAL 150 100%
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multicentric nature of the survey and changes in the
clinical practice and indications for surgery over the
years, including the type of procedure.
Professional caregivers
Most pediatric patients were followed by pediatric endo-
crinologists (7/10), pediatricians with a special interest
in XLH (2/10) and pediatric nephrologists (1/10). In all
cases a multidisciplinary team, including orthopedic sur-
geons, radiologists, dentists, and possibly geneticists
were activated. Neurologists, neurosurgeons, physical
therapists were also involved in the team, though less
frequently.
During the time frame of the survey, 63 patients had
reached adult age. Of these, 31 continued to be followed
in pediatric centers (11 aged 18–25 years, and 22 aged >
25 years). The remaining adult patients were addressed to
adult endocrinologists, nephrologists or rheumatologists.
Disease burden
Quality of life (QoL) data were not available due to the
retrospective nature of the study. Nonetheless, experts
participating in the study were asked to estimate the im-
pact of the disease on patients, using a 5-point scale (1:
low impact, 5: high impact), inspired from the EUROQOL
questionnaire, which explored several dimensions of daily
life (functional capacity, mobility, usual activities, pain/dis-
comfort). The estimated impact of the disease on daily life
ranked on average 4.5 for patients with severe disease, 3.7
for patients with moderate disease and 1.8 for those with
mild symptoms. “Severe” disease corresponded to patients
with severe leg deformities as defined above and/or major
complications, “moderate” to moderate bone changes and
limited complications, such as dental malpositions, and
“mild” to the remaining patients. As expected, rickets sec-
ondary to vitamin D deficiency ranked best (1.8). Osteope-
trosis ranked worst (4.61) and XLH had and intermediate
score of 3.5 (Table 4). These estimates are clearly limited
by the retrospective nature of the survey and reflect physi-
cian’s opinion and not patient perception.
Discussion
XLH is a rare inherited disease, characterized by rickets
and abnormal renal phosphate losses. Unrestricted ex-
pression of the phosphaturic hormone fibroblast growth
factor 23 (FGF23) secondary to PHEX mutations cause
most symptoms. Animal studies demonstrate that inacti-
vation of PHEX increases FGF23 levels, which downre-
gulates sodium-dependent phosphate transporters and 1
alpha hydroxylation of 25(OH)-vitamin D in renal prox-
imal cells. The mechanisms by which PHEX mutations
cause FGF23 production are still poorly understood.
However, experimental and clinical data show that neu-
tralizing antibodies against FGF23 prevent most XLH
symptoms, thus demonstrating that this hormone is the
principal culprit in this disease [10, 11].
Symptoms are mainly related to rickets in children
and osteomalacia in adults, which cause different
Fig. 1 Severity of symtoms
Table 3 Prevalence of other XLH-related symptoms
Disease Yes No
Reduced Muscular Force 66% 34%
Dental malpositions 53% 47%
Dental abscess 33% 67%
Osteopenia 16% 84%
Pathological fractures 13% 87%
Neurological problems 12% 88%
Hearing impairment 7% 93%
Craniosynostosis 6% 94%
Table 4 Ranking of disease severity according to physicians
Disease Mean SD
Osteopenia 4.61 0,70
Osteogenesis imperfecta 4.45 0,60
McCune-Albright syndrome 3.95 0,50
Achondroplasia 3.85 0,82
XLH 3.55 0,50
Autosomal dominant hypophosphatemic
rickets (FGF23 mutation)
3.50 0,71
Vitamin D deficiency 1.80 0,63
1 = Low impact; 5 = High impact
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complications. XLH during childhood manifests mainly
with bone deformities (bowed legs, genu varum or val-
gus, rachitic rosary, dolichocephaly), short stature, bone
pain and dental abnormalities. The diagnosis is often
delayed, which can significantly impact on long-term
outcome [5, 6].
Conventional therapy includes supplementation with
active vitamin D analogues and with oral phosphate
salts. In most patients, symptoms improve, but the dis-
ease is not cured by conventional therapy [2]. This is
most likely related to direct effects of high FGF23 levels
on peripheral tissues, which are not inhibited by conven-
tional treatment and may even be enhanced, since
FGF23 levels increase in treated children [2]. Moreover,
treatment is limited by side effects, in particular hyper-
parathyroidism and nephrocalcinosis that frequently de-
velop when using high doses of therapy.
The present study was conducted to evaluate the
current status in the diagnosis and treatment of XLH in
Italy. Overall, results are in line with available data in
the literature, although with some noticeable differences.
The prevalence of XLH is estimated between 1.2–3.0/
60,000 [12, 13]. The expected number of prevalent
pediatric patients with XLH in Italy is 187–470, consid-
ering an overall population of 9.374.322 persons aged 0–
17 years. Our survey included 150 children diagnosed
over a period of 20 years in 10 Italian centers with high
experience in treating XLH. This number is lower than
expected, indicating that the disease is either underdiag-
nosed or often treated in less specialized centers.
The diagnosis of XLH is based on clinical, radiological
and biochemical grounds and can be confirmed by dem-
onstrating a PHEX mutation. A positive X-linked family
history usually confirms the diagnoses. When genetic
analysis is not available and family history is absent, the
disease is presumed, but cannot be demonstrated. In
other cohorts, positive family history is observed in ap-
proximately 60% of cases [14, 15], as opposed to 33% in
our survey. Most patients in which genetic testing was
performed however, had a positive mutation, including
patients with negative family history. It is unlikely that
de novo mutations are more frequent in Italy. Most
likely, parents of many patients were poorly symptom-
atic and/or reliable family history could not be traced
back from medical records.
Our patients had overt symptoms with similar fre-
quencies to those reported in the literature, with the ex-
ception of Chiari malformation and craniosynostosis.
These are probably underdiagnosed because radiologic
investigations, including brain MRI, are not routinely
performed in most centers.
Conventional treatment usually improves bone pain
and other XLH features but carries the risk of causing
hyperparathyroidism and/or nephrocalcinosis. In the
clinical practice, PTH levels, urinary calcium excretion
and renal ultrasound are evaluated at regular interval to
adapt treatment. Overall, nephrocalcinosis has been re-
ported in the literature in 30–70% of patients [13, 15–
17]. In the vast majority of cases, renal function is pre-
served, but very long-term data are not available yet.
Most publications report a positive relationship between
oral phosphate doses and nephrocalcinosis, whereas the
association with vitamin D therapy is less strong [13,
17–19]. No increase in the supersaturation of either cal-
cium oxalate or phosphate in urines was observed in
one study including 20 patients with XLH [20]. Conceiv-
ably, the incidence observed in the Italian cohort is
lower than previously reported (34%) because physicians
have learned to balance treatment to avoid this compli-
cation. Hydrochlorothiazide has been shown to decrease
calciuria in XLH [21] and potassium citrate may help
preventing calcium precipitation. The prescription of
these treatments was not included in the survey.
The incidence of hyperparathyroidism was more diffi-
cult to estimate because PTH levels are known to fluctu-
ate overtime. Due to the retrospective nature of the
survey only tertiary hyperthyroidism was evaluated and
was diagnosed in 6% of patients.
Likewise, indication for orthopedic surgery in XLH are
not clearly established and surgical attitudes have chan-
ged over the years [22–25]. If possible, osteotomies are
performed preferentially after completion of growth [22,
26]. The only consistent finding in our survey was the
increased use of epiphisiodesis in most recent years in
all centers, while the overall number of surgeries did not
change substantially overtime.
As expected, XLH has a negative impact on patient’s
life. Most patients treated with conventional therapy are
not cured and continue to experience complications re-
lated to their disease. The majority of children in this
survey had normal daily activities despite their physical
impairment. The impact in adults could not be esti-
mated, due to the limited number of patients. However,
data in the literature show that QoL in these patients
can be severely affected [7, 27].
Conclusion
This survey investigated the epidemiology, diagnosis and
treatment of XLH in Italy. Despite its limitations, it
highlights the severity of the disease and lack of homo-
geneity in treatment attitudes among specialists. Most
importantly, results show a number of unmet needs and
the limitations of conventional treatment that cannot
cure the disease. In addition, these may cause adverse
events, particularly when high dosages are used.
New therapies with anti-FGF23 antibodies are likely to
modify the prognosis of XLH in the future [28–30].
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Endnotes
1Participating centers included: Bambino Gesù Chil-
dren’s Hospital – Rome (F.E. and M.C.), Borgo Roma
Hospital-University of Verona – Verona (F.A.), Istituto
Auxologico Italiano IRCCS – Milan (M.L.B. and I.C.),
IRCCS Cà Granda Foundation-Maggiore Policlinico
Hospital – Milan (C.E.V.), Giannina Gaslini Institute –
Genoa (N.D.I. and M.M.), S. Orsola Malpighi University
Hospital – Bologna (A.C., A.B. and F.B.), Regina Mar-
gherita Children’s Hospital, University of Turin – Turin
(L.D.S. and D.T.), University Hospital of Pisa – Pisa
(G.B.), IRCCS San Raffaele Hospital-Vita-Salute San Raf-
faele University – Milan (G.W. and S.M.), Careggi Uni-
versity Hospital-University of Florence – Florence
(M.L.B.).
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